<DOC>
	<DOCNO>NCT00145509</DOCNO>
	<brief_summary>The primary objective trial characterize long-term ( 40 week ) safety tolerability asenapine bipolar I disorder subject completely respond continue treatment lithium valproic acid ( VPA ) treatment acute manic mixed episode upon enrollment 12-week lead-in trial , A7501008 ( NCT00145470 ) . The safety comparison group receive lithium VPA placebo group receive lithium VPA asenapine , caveat subject may receive benzodiazepine and/or antidepressant rescue medication need .</brief_summary>
	<brief_title>40 Week Trial Study Safety Asenapine When Added Lithium Valproate Treatment Bipolar Disorder ( A7501009 ) ( P05786 )</brief_title>
	<detailed_description />
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<criteria>Have bipolar I disorder ( current episode manic mixed ) , treat lithium valproic acid , complete 12week leadin trial Have unstable medical condition clinically significant laboratory abnormality . Have primary diagnosis bipolar I disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>